Clinical Trial Update: Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is investigating whole-body quantification of HER2 with 89Zr-trastuzumab PET/CT to assess tracer accumulation in HER2-overexpressing or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Lung Cancer (NSCLC), HER2 Expression | Phase 1 | Status: NOT_YET_RECRUITING